Registry for patients with AL amyloidosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This registry aims to collect comprehensive data from patients diagnosed with AL amyloidosis, both at the time of diagnosis and during follow-up. By gathering this information, researchers will be able to describe the natural history of the disease in a real-world context. The registry will also help in defining and validating prognostic models, as well as criteria for response and relapse throughout the course of the disease.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. diagnosis of systemic AL amyloidosis;
2. treatment-naïve (pre-treatment data collected at participating center available for retrospective part);
3. age ≥18 years;
4. ability to understand and willingness to sign an informed consent (patients who already sign informed consent for clinical data to be used in retrospective analyses will be accepted);
5. planned (or ongoing) follow-up at participating center.

Exclusion Criteria:

1. non-AL amyloidosis;
2. previous treatment for AL amyloidosis.

Where it's running

• Fondazione IRCCS Policlinico San Matteo
  Pavia, Italy Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SMS text check-ins to track symptoms for people with plasma cell disorders

  This study tests whether daily SMS symptom prompts are feasible and acceptable for adults starting treatment for multiple myeloma or AL amyloidosis.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07850284

• Hungarian National Systemic Amyloidosis Registry

  This registry collects medical data from adults with systemic amyloidosis across Hungary to help understand how the disease is diagnosed and treated in real-world practice.

  Recruiting at 12 sites Semmelweis University · Balatonfüred and 11 other locations · NCT07689331

• Tec Dara for newly diagnosed multiple myeloma with light chain amyloidosis

  This study tests whether tec listamab plus daratumumab can help newly diagnosed multiple myeloma with AL amyloidosis and whether the combination is safe.

  Recruiting Phase 2 Shanghai Zhongshan Hospital · Shanghai · NCT07638683

• How the IGLV1-44 light chain causes AL amyloidosis and POEMS

  This project tests whether specific IGLV1-44 light‑chain sequences drive AL amyloidosis and POEMS and whether nanobodies can recognize and stabilize those light chains in adults with AL amyloidosis, POEMS, or multiple myeloma.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia · NCT07448935

• How N-glycosylation of light chains affects AL amyloidosis diagnosis and treatment

  This project will test whether a sugar modification called N-glycosylation on immunoglobulin light chains helps cause disease or changes how AL amyloidosis and related monoclonal gammopathies behave in adults.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia, PV · NCT07448779

• Belgian Amyloidosis Biobank and Patient Registry at UZ Leuven

  This project collects and stores blood, tissue samples, and medical data from adults with suspected or confirmed amyloidosis to create a biobank and registry for future research.

  Recruiting at 2 sites Universitaire Ziekenhuizen KU Leuven · Leuven and 1 other locations · NCT07172243

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.